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Background:  Soluble vascular cell adhesion molecule-1 (sVCAM-1) is upregulated on endothelial cells in the setting of inflammation, allowing 
monocyte adherence and infiltration. We examined whether sVCAM-1 was a predictor of cardiac events in patients with stable CAD.
Methods:  sVCAM-1 was measured (R&D Systems) in a pilot nested case-cohort study of 909 patients with stable CAD from the PEACE trial. 
Patients were divided into quartiles on the basis of sVCAM-1 levels. Multivariable Cox regression was used to adjust for clinical factors and other 
biomarkers.
Results:  Median sVCAM-1 level was 917 ng/ml (IQR 771-1127). Patients with elevated sVCAM-1 were more likely to be older, male, hypertensive, 
smokers, and diabetic, have lower cholesterol and eGFR, and less likely to be on lipid-lowering therapy. Higher sVCAM-1 levels were associated 
with an increased risk of CV death, MI, or stroke over a median of 4.8y of follow-up (Fig) with a HR 1.71 (95% CI 1.17-2.49) for Q2-4 vs Q1. There 
was directional consistency for CVD (HR 1.96), MI (HR 1.58), and stroke (HR 1.96). After adjustment for the aforementioned clinical factors and 
inflammatory biomarkers hsCRP and Lp-PLA2, the risk for CVD/MI/Stroke was partially but not completely attenuated (HR 1.38, 95% CI 0.91-2.10).
Conclusion: Higher sVCAM-1 levels are associated with an increased risk of CVD/MI/Stroke in patients with stable CAD. Expanded studies are 
warranted to quantify the magnitude of increased risk independently conferred by sVCAM-1. 
 
